Document 3134
 DOCN  M94A3134
 TI    Clinical progression in HIV1 and HIV2 infection.
 DT    9412
 AU    Vasconcelos C; Castro-Melo J; Carvalho MF; Santos E; Cerveira C;
       Sarmento R; Marques R; Campos M; Servico de Imunologia, Hosp. Sto.
       Antonio, Porto, Portugal.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(1):146 (abstract no. PB0010). Unique
       Identifier : AIDSLINE ICA10/94369441
 AB    INTRODUCTION, POPULATION AND METHODS: A rate of clinical progression
       slower for HIV2 than for HIV1 has been generally reported but never
       substantiated. In the present study the clinical evolution, evaluated by
       Walter Reed staging (WR 1 to 6), was studied by actuarial curves in HIV1
       (n = 50) and HIV2 (n = 36) patients matched by age and sex, selected
       from a larger cohort comprising patients from a variety of risk groups
       studied periodically before and after AZT antiretroviral therapy
       (anti-HIV). RESULTS: In patients before anti-HIV (HIV1 = 42; HIV2 = 31),
       progression to [WR5 or to WR6], but not to [WR6], was significantly
       different in the two groups (p = 0.002); in all patients, irrespectively
       of anti-HIV, progression to [WR5 or to WR6] or to [WR6] was also
       significantly different (p = 0.001 and p = 0.003 respectively).
       Progression to low numbers of CD4 cells (< 300/mm3) and to initiation of
       anti-HIV was not significantly different in HIV1 and HIV2. DISCUSSION:
       Our results provide evidence for a slower clinical course in HIV2
       infection. The recognized incapacity of AZT to significantly alter the
       clinical course of HIV infection, legitimates that our results are taken
       as representative of HIV1 and HIV2 diseases irrespective of the
       treatment status. The similar rates of progression of HIV1 and HIV2
       patients to low numbers of CD4 cells explains the similar rate of
       progression to initiation of anti-HIV which is timed by the numbers of
       CD4 cells. The contrast of a similar course of immunological parameters
       with the observed significant difference in the progression to late
       stages of disease, for HIV2 as compared with HIV1, confirms our clinical
       experience of a slower clinical progression with a similar decay in CD4
       cells. This may explain the contrast with previous reports on the
       evolution of immunological parameters in patients at the same clinical
       stage (what our results show to correspond to different time points for
       HIV1 and HIV2 disease) and suggests that, with current criteria, HIV2
       patients start anti-HIV earlier in the disease. The latter fact would
       account for the low number of non-treated HIV2 patients in WR6 and could
       explain that their progression to WR6 is non-significantly different
       from HIV1.
 DE    Acquired Immunodeficiency Syndrome/IMMUNOLOGY/*PHYSIOPATHOLOGY
       Actuarial Analysis  Age Factors  Comparative Study  Female  Human  HIV
       Seropositivity/IMMUNOLOGY/*PHYSIOPATHOLOGY  *HIV-1  *HIV-2  Male  Sex
       Factors  T4 Lymphocytes  MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).